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Abstract
Background: The autotaxin/lysophosphatidic acid axis is involved in diverse biological processes including neurodevelopment, 
inflammation, and immunological functioning. The lysophosphatidic acid 1 receptor has been implicated in the 
pathophysiology of major depressive disorder and in the mechanism of action of antidepressants. However, it is unclear 
whether central or peripheral autotaxin levels are altered in patients with major depressive disorder.
Methods: Serum autotaxin levels were measured by an enzyme-linked immunosorbent assay in 37 patients with major 
depressive disorder diagnosed using DSM-IV-TR who underwent electroconvulsive therapy and were compared with those 
of 47 nondepressed controls matched for age and sex between January 2011 and December 2015. Patient serum levels of 
autotaxin before and after electroconvulsive therapy were also compared. In a separate sample set, cerebrospinal fluid 
autotaxin levels were compared between 26 patients with major depressive disorder and 27 nondepressed controls between 
December 2010 and December 2015. A potential association was examined between autotaxin levels and clinical symptoms 
assessed with the Hamilton Depression Rating Scale.
Results: Before electroconvulsive therapy, both serum and cerebrospinal fluidautotaxin levels were significantly lower in 
major depressive disorder patients than in controls (serum: P = .001, cerebrospinal fluid: P = .038). A significantly negative 
correlation between serum, but not cerebrospinal fluid, autotaxin levels and depressive symptoms was observed (P = .032). 
After electroconvulsive therapy, a parallel increase in serum autotaxin levels and depressive symptoms improvement was 
observed (P = .005).
Conclusion: The current results suggest that serum autotaxin levels are reduced in a state-dependent manner. The reduction 
of cerebrospinal fluidautotaxin levels suggests a dysfunction in the autotaxin/lysophosphatidic acid axis in the brains of 
patients with major depressive disorder.
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Introduction
Autotaxin (ATX) is a secreted enzyme that produces the lipid me-
diator lysophosphatidic acid (LPA) from extracellular lysophos-
phatidyl choline(Umezu-Goto et  al., 2002)—it is the primary 
enzyme responsible for LPA production(van Meeteren et  al., 
2006). Lysophosphatidic acid exerts its effect through at least 
6 LPA G-protein-coupled receptors (LPAR)(Yung et al., 2015) and 
is involved in numerous biological processes, including neuro-
progenitor cell function(Yung et al., 2011), myelination(Anliker 
et  al., 2013), synaptic transmission(Trimbuch et  al., 2009), and 
the brain’s immunologic response(Schilling et al., 2004), which, 
in turn, influences neural development, function, and behavior. 
Autotaxin is widely expressed in brain as well as a number of 
peripheral tissues(van Meeteren et al., 2006)—the expression of 
LPAR is tightly linked with ATX(Frugier et al., 2011).
LPA has been implicated in a number of neurophysiological 
functions and neuropathologies(Yung et al., 2015). For example, 
LPAR1 knock-out mice exhibit depressive-like behaviors, includ-
ing hippocampal-dependent cognitive alteration (Santin et al., 
2009), hypoactivity (Castilla-Ortega et al., 2013), and anhedonia 
(Moreno-Fernandez et al., 2017). Decreased neurogenesis within 
the hippocampus of these mice was also observed (Matas-
Rico et  al., 2008). Interestingly, antidepressants bind to LPAR1 
expressed in brain astrocytes(Kajitani et al., 2016; Olianas et al., 
2016), activation of which leads to expression of glial cell line-
derived neurotropic factor (Kajitani et  al., 2016), an important 
mediator of major depressive disorder (MDD)(Takebayashi et al., 
2006; Uchida et al., 2011; Tsybko et al., 2017). These findings sug-
gest a possible association between LPAR1 and the pathophysi-
ology of MDD, which, in turn, could be targeted for the treatment 
of MDD. The linkage between the dysfunction of LPAR1 and that 
of the ATX/LPA axis has not been established, but the existence 
of such a linkage has been strongly suggested from preclinical 
findings. Specifically, the association between the ATX/LPA axis 
and MDD has yet to be clinically defined.
The current study examined whether ATX is altered in 
patients with MDD and if the alteration reflects the severity 
of depressive symptoms. While postmortem brain has been 
used for molecular research of psychiatric disorders, includ-
ing MDD, CSF and blood from living patients are preferred in 
order to understand the actual relationship between bio-mol-
ecules of interest and ongoing symptoms. In human serum, 
ATX is highly stable and does not greatly vary among healthy 
subjects(Nakamura et  al., 2008). By contrast, direct measure-
ment of LPA is challenging due to its instability(Aoki et  al., 
2002). Nonetheless, blood levels of ATX and LPA are significantly 
correlated(Hosogaya et al., 2008). Thus, levels of ATX could dir-
ectly reflect LPA levels and therefore serve as a proxy for ATX/
LPA axis activity. The current study measured serum and CSF 
levels of ATX in MDD patients.
Findings from preclinical studies indicate that the patho-
physiology of MDD is mediated in part by an abnormality of the 
ATX/LPA axis and that currently available therapeutic interven-
tions appear to modulate ATX functioning(Matas-Rico et  al., 
2008; Santin et  al., 2009; Castilla-Ortega et  al., 2013; Olianas 
et al., 2016; Kajitani et al., 2016; Moreno-Fernandez et al., 2017). 
To determine if in fact modulation of ATX in MDD patients is 
associated with symptom attenuation, the current study meas-
ured ATX levels in patients who underwent a therapeutic course 
of ECT.
METHODS
Patients
Serum samples were collected at the Department of Psychiatry 
of the National Hospital Organization Kure Medical Center 
(NHOKMC), Hiroshima, Japan between January 2011 and 
December 2015 (sample Set 1). Patients diagnosed as having MDD 
were recruited among inpatients who were scheduled for ECT, 
based on the guidelines of the American Psychiatric Association 
(American Psychiatric Association, 2001), at NHOKMC (n  =  37, 
Set 1; Table 1). Serum samples were collected just before the first 
ECT session (Pre-ECT; before any ECT session) and 2 weeks after 
the final ECT session (Post-ECT). Forty-seven subjects, with no 
history of past or current mental disorders, were recruited as 
nondepressed controls matched for age and gender. Most MDD 
patients at Pre-ECT received antidepressant pharmacotherapy: 
mirtazapine (15–45  mg/d; n  =  16), duloxetine (20–60  mg/d; 
n = 9), mianserin (10–60 mg/d; n = 6), paroxetine (10–40 mg/d; 
n = 5), escitalopram (10–40 mg/d; n = 5), nortriptyline (100 mg/d; 
n  =  5), trazodone (25–50  mg/d; n  =  3), imipramine (50  mg/d; 
n = 2), sulpiride (50 mg/d; n = 2), sertraline (100 mg/d; n = 1), and 
amoxapine (100 mg/d; n = 1). Fifteen patients received a com-
bination of 2 antidepressant drugs (paroxetine and mianserin, 
3; paroxetine and mirtazapine, 1; duloxetine and mirtazapine, 
4; sertraline and mirtazapine, 1; escitalopram and mirtazapine, 
1; imipramine and trazodone, 1; imipramine and mirtazapine, 
1; nortriptyline and mianserin, 1; nortriptyline and trazodone, 
1; nortriptyline and mirtazapine, 1), and 3 received a combin-
ation of 3 antidepressant drugs (escitalopram, mirtazapine, and 
Significance Statement
The autotaxin (ATX)/lysophosphatidic acid (LPA) axis is involved in diverse biological processes including neurodevelopment, 
inflammation, neurological, and immunological functioning. The LPA1 receptor has been implicated in the pathophysiology 
of depressive disorder and in the mechanism of action of antidepressants. The current study showed decreased levels of ATX, 
which produces LPA, the endogenous LPA1 receptor ligand, in both serum and cerebrospinal fluid (CSF) in patients with major 
depressive disorders (MDD) compared with ATX levels of nondepressed controls. Furthermore, serum levels of ATX increased 
following acute electroconvulsive therapy, which is a highly effective acute treatment for severe forms of depression. These find-
ings indicate that a decline in ATX/LPA axis function, as reflected by reduced expression of ATX, could be associated with the 
pathophysiology of MDD and that serum and CSF ATX measurements could be used as biomarkers for evaluating the efficacy of 
treatments in some MDD patients.
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sulpiride, 2; duloxetine, mirtazapine, and mianserin, 1). The 
mean imipramine (IMI) dose equivalence according to a previous 
report(Inada and Inagaki, 2015) at Pre-ECT was 225.7±151.6 mg/d. 
Three patients did not receive any antidepressant while under-
going the course of ECT.
In Set 2 (Table1), 26 MDD patients and 27 nondepressed con-
trol subjects, matched for age and gender, were recruited through 
advertisements in a free local magazine and an announcement 
at the NCNP website, between December 2010 and December 
2015. From these subjects, CSF was collected once.
Eight MDD patients received antidepressant pharmaco-
therapy: milnacipran (75–100  mg/d; n  =  2), sertraline (50–
100  mg/d; n  =  2), paroxetine (20–40  mg/d; n  =  2), sulpiride 
(100–300  mg/d; n  =  2), duloxetine (60  mg/d; n  =  1), escitalo-
pram (10 mg/d; n = 1), mirtazapine (30 mg/d; n = 1), mianserin 
(30 mg/d; n = 1), or imipramine (150 mg/d; n = 1). Three patients 
received a combination of 2 antidepressant drugs (paroxetine 
and mirtazapine, 1; sertraline and sulpiride, 1; escitalopram and 
milnacipran, 1), and 1 received a combination of 3 antidepres-
sant drugs (milnacipran, mianserin, and sulpiride). The mean 
IMI dose equivalence was 207.8 ± 109.6 mg/d. Eighteen patients 
did not receive any antidepressants.
In both sample sets, a consensus diagnosis was made by 
either trained psychologists or psychiatrists according to the 
DSM-IV-TR(American Psychiatric Association, 2000), on the basis 
of the Mini-International Neuropsychiatric Interview, Japanese 
version(Sheehan et al., 1998; Otsubo et al., 2005), additional un-
structured interviews, and information from medical histories. 
Exclusion criteria included a past or current history of other 
psychiatric disorders such as bipolar disorder, schizoaffective 
disorder or adjustment disorder, significant neurological illness, 
or any other significant medical illness, including inflammatory 
diseases such as liver disease, fibrosis, cancer, kidney disease, 
arthritis, and Alzheimer’s disease, as these conditions could 
be due to changes in the ATX/LPA axis(Umemura et  al., 2006; 
Benesch et al., 2016; Shimizu et al., 2016). In Set 1, a total of 6 
psychiatric patients displayed co-morbidities, including: 2 with 
generalized anxiety disorder, 2 with somatization disorder, 1 
with panic disorder, and 1 with obsessive-compulsive disorder. 
The severity of the comorbidities was mild. All patients in Set 2 
had no comorbidities. As for Set 1, if a patient received 2 or more 
acute ECT courses during the study period, the serum sample 
was collected at only the first acute ECT course.
Nondepressed subjects were screened based on either a clin-
ical interview or a structured interview by trained psychologists 
or psychiatrists using the Mini-International Neuropsychiatric 
Interview, Japanese version. The person who assessed them was 
not involved in the subsequent analysis of the data. With all 
participants, their past medical history, current illness, if any, 
and current medications were reviewed. Furthermore, hepatic 
enzyme, renal function, lipid, inflammatory indices, and nutri-
tional status of nondepressed subjects in Set 1 were screened 
by a blood test. As for Set 2, although subjects in Set 2 were not 
screened by a blood test, most subjects were younger than those 
in Set 1. Thus, rather than subject the patients to an unneces-
sary medical test, we determined that an interview for their past 
medical history, current illness, and current medication, if any, 
was sufficient.
Clinical symptoms in MDD patients were scored using 
the 17-item Hamilton Depression Rating Score [HDRS]. The 
17 items of the HDRS were assigned to the following 5 sub-
scales: core symptom (items 1, 2, 7, 8, 10, 13); sleep (items 4, 5, 
6); activity (items 7, 8); psychic anxiety (items 9, 10); and som-
atic anxiety (items 11, 12, 13)  in accordance with a previous 
report(Seretti et al., 1999). For Set 1, each patient’s symptoms 
were assessed at Pre-ECT session (baseline) and at Post-ECT by 
the same trained psychiatrist. The psychiatrist was not aware 
that patient ATX levels would be measured in serum or CSF 
and had no role in patient selection. Responders to ECT were 
defined as demonstrating a 50% decrease in HDRS score. For 
Table 1. Patient Characteristics
 
Serum Samples (Set 1) CSF Samples (Set 2)
MDD Set1 
vs Set2
MDD 
at Pre-ECT Controls P value MDD Controls P value
P value(n = 37) (n = 47)  (n = 26) (n = 27)  
Gender (female) 22 (59.5%) 28 (59.6%) 0.991a 13 (50.0%) 13 (48.2%) 0.893a .457c
Age (years) 58.7 ± 13.2 58.9 ± 11.4 0.953b 41.2 ± 7.3 41.9 ± 9.1 0.689b <.001d
Age of onset (years) 53.9 ± 14.2   30.2 ± 10.6   <.001d
Duration of current 
episode (months)
5.7 ± 6.2   ND   –
Psychotic features 15 (40.5%)   ND   –
Catatonic features 7 (18.9%)   ND   –
Number of episodes 1.5 ± 1.9   1.9 ± 1.2   .168d
Number of ECT 
sessions per course
10.0 ± 3.5   ND   –
Total HDRS 24.4 ± 8.3   11.8 ± 7.1   <.001d
IMI equivalence (mg/d) 225.4 ± 151.6   207.8 ± 109.6   .923d
Abbreviations: CSF, cerebrospinal fluid; ECT, electroconvulsive therapy; HDRS, Hamilton Depression Rating Scale-17; IMI, imipramine; MDD, major depressive disorder; 
ND, not detected. 
Serum samples (Set 1) and CSF samples (Set 2) were collected from separate facilities. Data shown as either mean ± SD or number (n) and percent of total (%). 
aComparison between MDD and control group by chi-square test.
bComparison between MDD and control group by Mann-Whitney U-test.
cComparison between MDD in Set 1 and Set 2 by chi-square test.
dComparison between MDD in Set 1 and Set 2 by Mann-Whitney U-test.
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Set 2, each patient’s symptoms were assessed by a trained 
psychologists or psychiatrists at the time of lumbar puncture. 
While there were 10 patients with moderate or higher depres-
sion state (HDRS ≥ 13), there were 10 patients with mild de-
pression state (HDRS ≤ 13) and 6 patients with remission state 
(HDRS ≤ 7).
After procedures were fully explained, written informed 
consent was obtained from all subjects. The current study was 
approved by the Ethics Committee of NHOKMC (27-09) and the 
Ethics Committee of NCNP (A2014-141).
Electroconvulsive Therapy (ECT) Procedures
ECT was performed according to previously described 
procedures(Shibasaki et  al., 2016; Itagaki et  al., 2017). Before 
undergoing ECT, each patient was screened for general health 
through laboratory tests such as blood test and urinalysis, and 
physical examination to exclude significant medical illness or 
clinical symptoms. Anesthesia was induced with i.v. thiamylal 
sodium (2–3  mg/ kg) and suxamethonium chloride (0.5–1  mg/
kg, i.v.). A  Thymatron System IV brief pulse square wave ap-
paratus (Somatics Inc., Lake Bluff, IL) was used to induce elec-
troconvulsions. Bilateral frontal-temporal electrodes were 
used as all ECT patients presented as severe, life-threatening 
cases(American Psychiatric Association, 2001). Only one ad-
equate seizure was required for each session, which was 
defined as an electroencephalographic seizure lasting more 
than 25 seconds with a high amplitude, slow wave, and postic-
tal suppression. The initial stimulus dose was determined using 
the half-age method(Petrides and Fink, 1996). If an adequate 
electroencephalographic seizure occurred in one session, the 
same stimulus energy was used at the next session. The max-
imum number of stimulations for each treatment session was 
2. Electroconvulsive therapy was administered a maximum of 3 
times per week and continued until the patient became asymp-
tomatic or the attending psychiatrist determined that the pa-
tient had obtained the maximum benefit within 3 to 15 sessions 
(mean: 10.0 ± 3.5; Table 1). After the purpose and the ECT pro-
cedure were described in detail, written informed consent was 
obtained from patients or caregivers of patients prior to initiat-
ing ECT. During the ECT course, medications were permitted and 
titrated as needed.
Collection of Serum and CSF Samples
After an overnight fast, venous blood (Set 1) was taken in the 
morning (between 7:00 and 8:00 am) before (Pre-ECT) and after 
(Post-ECT) ECT at NHOKMC. Blood samples were drawn into 
anticoagulant-free tubes and kept at room temperature for 1 
hour. Serum was separated by centrifugation at 3000 rpm for 15 
minutes at 4°C and stored at −80°C until assay.
Cerebrospinal fluid (Set 2) was obtained by lumbar puncture 
between 10:00 am and 4:00 pm. Following application of local an-
esthetic, CSF was obtained by lumbar puncture at either L3–4 
or L4–5 using an atraumatic pencil point needle (Uniever 22G, 
75  mm, Unisis Corp, Tokyo, Japan). Eight mL of CSF was col-
lected and immediately chilled on ice. The CSF was centrifuged 
at 4000 g for 10 minutes at 4°C, and the supernatant was dis-
pensed into 0.5-mL aliquots in tubes and stored at −80°C until 
assay. Selected CSF samples were thawed (in ice-cold water), 
dispensed, and refrozen. CSF samples contaminated with blood 
were excluded from further analysis. While more depressed 
patients could have been sampled for CSF, it is challenging to 
subject severely depressed patients to a spinal tap.
Detection of ATX by Enzyme-Linked 
Immunosorbent Assay
All serum and CSF samples were brought to room temperature 
before use in an enzyme-linked immunosorbent assay. Serum 
and CSF ATX levels were determined with a Quantikine human 
ATX immunoassay (R&D Systems, Minneapolis, MN) following the 
manufacturer’s procedure. Quantification was performed with a 
Multi-Spectrophotometer Viento Microplate Reader (Sumitomo 
Dainippon Pharma Co, Osaka, Japan). The person performing the 
ATX assays at NHOKMC was unaware of the treatment status of 
the patients from whom the samples were obtained.
Statistical Analysis
Data are shown as mean  ±  SD. Tests for normality were per-
formed using the Shapiro-Wilk and the Kolmogorov-Smirnov 
tests, and data were analyzed with nonparametric tests (SPSS 
version 22.0 for Windows, IBM Japan Corporation, Tokyo, Japan). 
Comparisons of parameters between patients with MDD and 
nondepressed controls were evaluated using the Mann-Whitney 
U-test. A  chi-square test was used for categorical variables. 
A  linear regression analysis was performed to evaluate pos-
sible relationships between serum and CSF ATX levels and clin-
ical parameters, diagnosis, and clinical symptoms, controlled 
for gender. Repeated-measures ANOVA was used to compare 
the parameters between Pre-ECT and Post-ECT, controlled for 
gender. Statistical significance was defined as a 2-tailed P < .05.
RESULTS
Clinical Data
Patient characteristics of MDD patients and nondepressed 
controls for Set 1 and Set 2 are presented in Table 1. Distribution 
by gender within and between Set 1 and Set 2 did not signifi-
cantly differ. However, patients in Set 1 were significantly older, 
and their onset of illness was earlier compared with subjects in 
Set 2. Patients with MDD in Set 1 had significantly higher HDRS 
compared with MDD patients in Set 2. There was no statistically 
significant difference in IMI equivalence doses.
Relationship Between Serum and CSF Levels of ATX 
and Gender in All Samples
The mean serum ATX level for females was significantly higher 
than that of males (213.4 ± 51.7 vs 151.8 ± 32.8 ng/mL, P < .001). 
The mean CSF ATX level for females was also significantly 
higher than that of males (281.1 ± 33.5 vs 257.8 ± 26.8 ng/mL, 
P = .007). These results indicate a gender-based difference in ATX 
levels in both serum and CSF, which was confirmed by linear re-
gression analysis (Table 2; serum: nonstandardized coefficient 
β = −61.6, P <  .001; CSF: nonstandardized coefficient β = −23.6, 
P = .005). Because of the gender-based difference, further analy-
ses of ATX levels were performed adjusting for gender.
Relationship Between Serum and CSF Levels of ATX 
and Other MDD Patient Characteristics
No significant correlations were observed between either serum 
or CSF ATX levels and clinical characteristics such as age, age 
of onset, duration of current episode, number of episodes, body 
weight, body mass index, smoking history, use of nonsteroidal 
antiinflammatory drugs, and IMI equivalence dose (Set 1 and 2; 
data not shown).
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There was no significant association of serum ATX levels 
with hepatic enzyme, lipid, inflammatory indices, or nutritional 
status, such as GOT, GPT, γ-GTP, total bilirubin, total cholesterol, 
low-density lipoprotein, high-density lipoprotein, triglyceride, 
C-reactive protein, leukocyte count, total protein, or albumin in 
the MDD group (Set 1; data not shown).
Serum and CSF Levels of ATX in the MDD Group 
Compared With the Control Group
The mean serum levels of ATX in MDD patients at Pre-ECT 
and nondepressed controls in Set 1 were 171.1 ± 46.3 and 
202.1 ± 56.3  ng/mL, respectively (Figure 1). The mean CSF lev-
els of ATX in MDD patients and nondepressed controls in Set 
2 were 260.7 ± 37.6  ng/mL and 277.4 ± 24.0  ng/mL, respectively 
(Figure 1). Serum ATX levels in patients with MDD were signifi-
cantly lower than those of nondepressed controls as demon-
strated by linear regression analysis adjusted for gender (Table 
2; nonstandardized coefficient β  =  −30.998, P  =  .001). CSF ATX 
levels in MDD patients were also significantly lower than those 
of nondepressed controls (Table 2; nonstandardized coefficient 
β = −17.186, P = .038).
Correlation Between Serum and CSF Levels of ATX 
and Clinical Symptomatic Scores in MDD Patients
Correlation coefficients were calculated between serum and 
CSF levels of ATX and HDRS for each MDD group using linear 
regression analysis, adjusting for gender and age (Figure 2). In 
the serum samples from MDD patients (Set 1) before undergoing 
ECT, there was a significant negative correlation between serum 
levels of ATX and total HDRS score (Figure 2; nonstandardized 
coefficient β = −1.714, P = .032). Furthermore, a negative correl-
ation between serum levels of ATX and subscale HDRS scores 
(activity) was observed (nonstandardized coefficient β = −9.491, 
P  =  .033). Higher serum levels of ATX were associated with a 
trend in lower subscale HDRS scores (core symptom, somatic 
anxiety, delusion, nonstandardized coefficient β = −3.722, −6.542, 
and −6.602; P =  .064, .053, and .095, respectively). On the other 
hand, in Set 2, CSF levels of ATX did not correlate with total 
HDRS score (nonstandardized coefficient β = −1.341, P = .186) as 
well as subscale HDRS scores (data not shown).
Alterations of Serum Levels of ATX in the MDD 
Group Over the Course of ECT
In Set 1, 30 of 37 serum samples from MDD patients (female: 
17, male: 13)  were collected after ECT. A  total of 7 serum 
samples were eliminated from analysis: 2 patients withdrew 
their consent, 4 patients were temporarily discharged, and 1 
had a fever. Among the 30 patients, HDRS scores for depres-
sive symptoms were significantly decreased following ECT 
(Pre-ECT: 24.4 ± 8.3, Post-ECT: 5.0 ± 2.9; P < .001). Twenty-eight 
of 30 patients with MDD (93.3%) responded to ECT with a 
50% or more decrease in HDRS score. There was no signifi-
cant difference in the IMI equivalence dose between Pre-
ECT and Post-ECT (Pre-ECT: 207.1 ± 167.1  mg/d and Post-ECT: 
Table 2. Multivariate Linear Regression Analyses Between Serum and CSF ATX Levels, Diagnosis
 
Serum ATX at Pre-ECT (Set 1) CSF ATX (Set 2)
Nonstand-
ardized Co-
efficient β (95% CI) P value
Nonstand-
ardized Co-
efficient β (95% CI)
P 
value
Constant 227.034 (212.535–241.534) <.001* 289.670 (275.585–303.754) <.001*
Diagnosis (control = 0/MDD = 1) -30.998 (-49.598 –-12.397) .001* -17.186 (-33.350–-1.022) .038*
Gender (female = 0/male = 1) -61.606 (-80.419–-42.793) <.001* -23.599 (-39.763–7.435) .005*
 R2 = 0.398, P < .001 R2 = 0.205, P = .003
Abbreviations: CSF, cerebrospinal fluid; ATX, autotaxin; MDD, major depressive disorder. Serum samples (Set 1) and CSF samples (Set 2) were collected from separate 
facilities. The horizontal bars represent the mean values adjusted for gender. *P < .05.
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Figure 1. Scatter plot of serum levels of autotaxin (ATX) (A) before a course of 
electroconvulsive therapy (ECT) and cerebrospinal fluid (CSF) levels of ATX (B) in 
control group (female: ▲; male: △) and major depressive disorder (MDD) group 
(female: ●; male: ○). Serum samples (Set 1) and CSF samples (Set 2) were collected 
from separate facilities. The horizontal bars represent the mean values adjusted 
for gender. *P < .05. 
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184.2 ± 97.1 mg/d, P = .409). Of the 37 patients that completed 
their course of ECT, serum samples from 30 patients were 
obtained. There were no statistically significant differences, 
including age, gender, HDRS score before and after ECT, and 
the number of ECT sessions received by each patient, be-
tween the 7 patients whose serum was not obtained and the 
30 patients from whom serum was obtained (data not shown). 
Serum levels of ATX before ECT also did not differ between 
these 2 groups (data not shown).
The mean serum levels of ATX before and after ECT were 
169.6 ± 46.3 and 186.9 ± 51.4 ng/mL, respectively. There was a 
statistically significant increase in serum levels of ATX in the 
MDD group over the course of ECT (Figure 3A; P = .001, repeated-
measures ANOVA, adjusted for gender). Notably, 2 nonrespond-
ers to ECT showed slightly decreased rather than increased ATX 
levels after ECT. Correlation coefficients were calculated be-
tween serum levels of ATX and HDRS scores, combining results 
before and after ECT. There was a significant negative correl-
ation between increased serum levels of ATX and decreased 
total HDRS score after ECT (Figure 3B; nonstandardized coeffi-
cient β = −1.243, P = .005).
Discussion
Both serum and CSF ATX were significantly reduced in MDD 
patients, and Pre-ECT ATX serum levels and depressive symp-
toms were negatively correlated. Furthermore, serum levels 
of ATX increased following ECT. In the current study, antide-
pressants did not appear to directly affect ATX levels as no 
correlations were observed between ATX levels and IMI dose 
equivalence (serum: nonstandardized coefficient β  =  0.065, 
P =  .154, CSF: nonstandardized coefficient β = −0.140, P =  .159) 
and between IMI dose equivalence before and after ECT. Also, 
in rat brain, chronic antidepressant treatment did not affect ei-
ther mRNA or protein expression of ATX (supplementary Figure 
1). The current findings indicate that alterations of ATX, which 
produces LPA, in part, could underlie the pathophysiology and 
symptomology of MDD. However, there was no significant cor-
relation in ATX CSF levels with severity of depression (HDRS), 
and the reason for this might be due to the limited number of 
patients and the inclusion of patients with either mild depres-
sion or patients who were in remission.
Autotaxin is abundantly expressed in brain glial cells, which 
play an important role in the pathophysiology of depression. 
Autotaxin mRNA is widely expressed in adult tissue, particu-
larly in the brain(Fuss et  al., 1997). In the adult brain, ATX is 
restricted to early and differentiating oligodendrocyte lineage 
cells and reactive astrocytes and choroid plexus epithelial and 
leptomeningeal cells(Savaskan et al., 2007). Brain glial cells such 
as oligodendrocyte and astrocytes are suggested as important 
sources of ATX(Savaskan et al., 2007; Zhang et al., 2014). Brain 
imaging and postmortem evaluation of the brain from MDD 
patients showed robust glial abnormalities such as decreased 
oligodendrocyte and astrocyte density and reduced expression 
of genes related to oligodendrocyte and astrocyte function(Tham 
et  al., 2011; Wang et  al., 2017). In addition, preclinical animal 
models of depression exposed to chronic stress showed mor-
phological and numerical decreases in cortical, hippocam-
pal, and amygdalar oligodendrocytes(Banasr et  al., 2007; Czeh 
et al., 2007) and astrocytes(Banasr et al., 2010; Gong et al., 2012; 
Rajkowska and Stockmeier, 2013; Sanacora and Banasr, 2013), 
which support findings from brains of MDD patients(Rajkowska 
and Stockmeier, 2013; Rajkowska et al., 2015). These results sug-
gest a potential linkage between MDD and a reduction of glia, 
which is a key source of ATX and could explain the reason for 
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Figure 2. Correlation between serum levels of autotaxin (ATX) before a course of 
electroconvulsive therapy (ECT) and total Hamilton Depression Rating Scale-17 
(HDRS) score in patients with major depressive disorder (MDD). The correlation 
coefficient was calculated by linear regression. Female values (●), n = 22; male 
values (○), n = 15. The dashed line represents the approximate correlation curve 
adjusted for gender. *P < .05. 
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Figure 3. (A) Serum levels of autotaxin (ATX) before and after a course of electro-
convulsive therapy (ECT) in the major depressive disorder (MDD) group, Set 1. (B) 
Correlation between serum levels of ATX and total Hamilton Depression Rating 
Scale-17 (HDRS) score at Pre/Post-ECT in the MDD group, Set 1. The correlation 
coefficient was calculated by linear regression. Pre-ECT female values (●), n = 17; 
male values (○), n = 13. Post-ECT female values (■), n = 17; male values (□), n = 13. 
The horizontal bars represent mean values. The dashed line represents the ap-
proximate correlation curve adjusted for gender. *P < .05. 
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the decreased levels of ATX in MDD patients. By contrast, elec-
troconvulsive seizure treatment in rats increased the number 
of newly divided cells expressing oligodendrocyte markers in 
the frontal cortex(Madsen et al., 2005). Electroconvulsive seizure 
also significantly increased the expression of glial fibullary 
acidic protein, a marker of reactive astrocytes, in the rat frontal 
limbic system(Kragh et al., 1993). These preclinical findings in 
combination with the current clinical findings suggest that 
amelioration of MDD by ECT could be mediated by an induction 
of the proliferation of oligodendrocyte and reactive astrocytes, 
thereby increasing ATX levels.
Another possibility is that chronic stress could be involved 
in the regulation of ATX expression. MDD is characterized 
by abnormal physiological responses to chronic stress. One 
likely source of serum ATX is adipose tissue(Ferry et al., 2003). 
Hypercortisolemia has been attributed to hypothalamic–pitu-
itary–adrenal (HPA) axis dysregulation, a consistent biological 
response to chronic stress in MDD(Kunugi et al., 2006). Chronic 
treatment with prednisolone, which induces hypercortisolemia 
and changes in the HPA axis, decreases serum levels of ATX in 
humans by changing adipose tissue ATX expression(Sumida 
et  al., 2013). This finding suggests reduced expression of ATX 
levels in MDD could be mediated through and a dysfunctional 
HPA axis. It is possible that a dysfunctional HPA axis could have 
mediated the decreased ATX observed in MDD patients in the 
current study, but measurement of serum or CSF cortisol will be 
needed to show a relationship between these parameters and 
alteration of ATX levels in MDD patients.
To place the current findings into perspective, there are a few 
limitations that should be mentioned. While the total sample 
size of the current study was not very large, significant corre-
lations were nonetheless observed. It is possible that some of 
the changes in serum ATX levels following ECT could be due in 
part to a placebo response, but there were only 2 patients who 
did not respond to ECT, so this possibility could not be tested in 
the current study. While withholding treatment in the current 
study would have been unethical, examination of more patients 
in which ECT failed to alleviate symptoms would determine the 
extent, if any, of a placebo effect on ATX expression. Secondly, 
ATX, but not LPA, was measured. Measurement of LPA levels and 
its species requires the use of an enzymatic cycling assay and 
liquid chromatography/mass spectrometry, respectively(Kurano 
et al., 2015). Furthermore, the currently obtained samples, both 
serum and CSF, may not be used to measure LPA since sam-
pling conditions were not under stringent conditions needed to 
ensure LPA stability(Hosogaya et al., 2008). Although there is a 
strong association between peripherally expressed ATX and LPA 
in humans(Watanabe et al., 2007; Masuda et al., 2008), the cor-
relation between ATX and LPA levels in MDD patients is unclear. 
The correlation between peripheral blood and CSF ATX levels is 
not clear, though there could be a linkage between CSF and per-
ipheral ATX levels as the current study showed decreased levels 
of ATX in both serum and CSF. An exact correlation may be diffi-
cult to obtain as there are technical difficulties with measuring 
LPA levels and there are a number of LPA species(Kurano et al., 
2015). Further confirming the suitability of ATX levels as a surro-
gate to LPA activity could also be performed in preclinical mod-
els of depression by demonstrating a relationship between ATX 
and LPA levels in the periphery and in the CSF from the same 
MDD patient. Finally, only one factor in a biological cascade was 
measured without exploring a possible relationship between 
ATX levels and inflammation/immunological indices, such as 
cytokines. If inflammation, via the ATX/LPA axis mediates MDD, 
then future studies will need to demonstrate a relationship 
between ATX levels and inflammation/immunological indices, 
perhaps by utilizing fluids from the same patient.
The current study confirmed previous findings that the 
serum concentration of ATX in women is significantly higher 
than that of men(Nakamura et  al., 2008). Since ATX is essen-
tial for stabilization of blood vessels and angiogenesis(Tanaka 
et al., 2006; van Meeteren et al., 2006) and is produced in adi-
pocytes, higher levels in females could reflect basic biological 
differences or the higher body fat ratio found in women com-
pared with men(Blaak, 2001). On the other hand, no significant 
difference was observed in CSF ATX concentrations between 
nondepressed males and females using a 2-site immunoenzy-
metric assay(Nakamura et  al., 2009). In the current study, not 
only serum but also CSF ATX levels in women were significantly 
higher than those in men. This discrepancy could be due to a 
limited number of patients (n = 53) and a difference in the quan-
tification method used in the current study compared with pre-
vious studies. There was no correlation between age and either 
serum or CSF ATX levels in females (serum: nonstandardized 
coefficient β = −0.182, P = .757; CSF: nonstandardized coefficient 
β = −0.629, P = .926), and between postmenopausal and serum or 
CSF ATX levels in females (serum: nonstandardized coefficient 
β = 6.226, P =  .737; CSF: nonstandardized coefficient β = 9.712, 
P  =  .613), suggesting that there is no correlation between ATX 
levels and menopausal status. However, a future study should 
address potential relationships between menstrual and meno-
pausal status and ATX levels.
In conclusion, the current study found, for the first time, that 
both serum and CSF levels of ATX were significantly decreased in 
MDD patients compared with nondepressed controls matched 
for age and gender. Also, there were significant correlations be-
tween depressive symptoms and serum levels of ATX. A course 
of ECT in MDD patients significantly increased serum levels 
of ATX. The findings suggest that alteration of ATX levels indi-
cate changes in levels of lysophospholipids such as LPA, which 
occurs as a cellular response to MDD and could reflect the se-
verity of depressive symptoms, which are, in turn, sensitive to 
ECT. Thus, the current findings lend support to the possibility 
that a decline in ATX, leading to decreased LPA, could be associ-
ated with the pathophysiology of MDD, and serum and CSF ATX 
measurement could be used as a biomarker for evaluating the 
efficacy of treatments in some MDD patients. However, in the 
current study, LPA levels were not directly quantified, given cur-
rent methodological limitations. Future studies, utilizing readily 
accessible quantification methods, should be able to demon-
strate a direct relationship between levels of ATX and LPA in 
MDD patients.
Supplementary Materials
Supplementary data are available at International Journal of 
Neuropsychopharmacology (IJNPPY) online.
Funding
This work was supported by a Grants-in-Aid from the Japan 
Society for the Promotion of Science (15K09819 to M.T., 
16K19796 to N.K., 16K18883 to M.O.-T., 15H02552 to Shigeto Y.); 
an Intramural Research Grant for Neurological and Psychiatric 
Disorders of National Center of Neurology and Psychiatry (24-
11, 27-1 to H.K.); Grant-in-Aid for Scientific Research (A) from 
the Ministry of Education, Science, Sports and Culture (25253075 
to H.K.), and Health and Labour Sciences Research Grants for 
Comprehensive Research on Persons with Disabilities from 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz005/5306018 by guest on 13 M
arch 2019
8 | International Journal of Neuropsychopharmacology, 2019
Japan Agency for Medical Research and Development (AMED) 
(15dk0310061h0001, 16dk0307062h0001 to H.K.); Integrated 
Research on Depression, Dementia and Development Disorders 
from AMED (18dm0107093h0003 to Shigeto Y.).
Acknowledgments
We are grateful to our colleagues for their tireless and expert 
assistance: Dr Hideo Kobayakawa, Dr Keigo Nakatsu, Dr Takashi 
Iwamoto, and Dr Motonobu Nakamura. We also thank Dr 
Yasutaka Fujita for establishing the patients’ database, Professor 
Junko Tanaka and Tomoyuki Akita for advice on statistical ana-
lysis, and Dr Aldric Hama for editorial assistance.
Interest Statement.
None.
References
American Psychiatric Association (2000) Diagnostic and statis-
tical manual of mental disorders: DSM-IV-TR, 4th ed. Wash-
ington, DC: American Psychiatric Association.
American Psychiatric Association (2001) The practice of electrocon-
vulsive therapy: recommendation for treatment, training, and 
privileging: a task force report of the American Psychiatric As-
sociation, 2nd ed.  Washington, DC: American Psychiatric Press.
Anliker  B, Choi  JW, Lin  ME, Gardell  SE, Rivera  RR, Kennedy  G, 
Chun  J (2013) Lysophosphatidic acid (LPA) and its receptor, 
LPA1, influence embryonic schwann cell migration, myelin-
ation, and cell-to-axon segregation. Glia 61:2009–2022.
Aoki  J, Taira  A, Takanezawa  Y, Kishi  Y, Hama  K, Kishimoto  T, 
Mizuno K, Saku K, Taguchi R, Arai H (2002) Serum lysophos-
phatidic acid is produced through diverse phospholipase 
pathways. J Biol Chem 277:48737–48744.
Banasr M, Valentine GW, Li XY, Gourley SL, Taylor JR, Duman RS 
(2007) Chronic unpredictable stress decreases cell prolifer-
ation in the cerebral cortex of the adult rat. Biol Psychiatry 
62:496–504.
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, 
Behar  KL, Sanacora  G (2010) Glial pathology in an animal 
model of depression: reversal of stress-induced cellular, 
metabolic and behavioral deficits by the glutamate-modulat-
ing drug riluzole. Mol Psychiatry 15:501–511.
Benesch  MG, Tang  X, Venkatraman  G, Bekele  RT, Brindley  DN 
(2016) Recent advances in targeting the autotaxin-lysophos-
phatidate-lipid phosphate phosphatase axis in vivo. J Biomed 
Res 30:272–284.
Blaak E (2001) Gender differences in fat metabolism. Curr Opin 
Clin Nutr Metab Care 4:499–502.
Castilla-Ortega E, Rosell-Valle C, Blanco E, Pedraza C, Chun J, Rod-
ríguez de Fonseca F, Estivill-Torrús G, Santín LJ (2013) Reduced 
wheel running and blunted effects of voluntary exercise in 
LPA1-null mice: the importance of assessing the amount of 
running in transgenic mice studies. Neurosci Res 77:170–179.
Czéh  B, Müller-Keuker  JI, Rygula  R, Abumaria  N, Hiemke  C, 
Domenici E, Fuchs E (2007) Chronic social stress inhibits cell 
proliferation in the adult medial prefrontal cortex: hemi-
spheric asymmetry and reversal by fluoxetine treatment. 
Neuropsychopharmacology 32:1490–1503.
Ferry G, Tellier E, Try A, Grés S, Naime I, Simon MF, Rodriguez M, 
Boucher J, Tack I, Gesta S, Chomarat P, Dieu M, Raes M, Gal-
izzi JP, Valet P, Boutin JA, Saulnier-Blache JS (2003) Autotaxin 
is released from adipocytes, catalyzes lysophosphatidic acid 
synthesis, and activates preadipocyte proliferation. Up-regu-
lated expression with adipocyte differentiation and obesity. J 
Biol Chem 278:18162–18169.
Frugier T, Crombie D, Conquest A, Tjhong F, Taylor C, Kulkarni T, 
McLean C, Pébay A (2011) Modulation of LPA receptor expres-
sion in the human brain following neurotrauma. Cell Mol 
Neurobiol 31:569–577.
Fuss B, Baba H, Phan T, Tuohy VK, Macklin WB (1997) Phospho-
diesterase I, a novel adhesion molecule and/or cytokine 
involved in oligodendrocyte function. J Neurosci 17:9095–
9103.
Gong Y, Sun XL, Wu FF, Su CJ, Ding JH, Hu G (2012) Female early 
adult depression results in detrimental impacts on the be-
havioral performance and brain development in offspring. 
CNS Neurosci Ther 18:461–470.
Hosogaya  S, Yatomi  Y, Nakamura  K, Ohkawa  R, Okubo  S, 
Yokota H, Ohta M, Yamazaki H, Koike T, Ozaki Y (2008) Meas-
urement of plasma lysophosphatidic acid concentration in 
healthy subjects: strong correlation with lysophospholipase 
D activity. Ann Clin Biochem 45:364–368.
Inada T, Inagaki A (2015) Psychotropic dose equivalence in Japan. 
Psychiatry Clin Neurosci 69:440–447.
Itagaki K, Takebayashi M, Shibasaki C, Kajitani N, Abe H, Okada-
Tsuchioka  M, Yamawaki  S (2017) Factors associated with 
relapse after a response to electroconvulsive therapy in uni-
polar versus bipolar depression. J Affect Disord 208:113–119.
Kajitani  N, Miyano  K, Okada-Tsuchioka  M, Abe  H, Itagaki  K, 
Hisaoka-Nakashima K, Morioka N, Uezono Y, Takebayashi M 
(2016) Identification of lysophosphatidic acid receptor 1 in 
astroglial cells as a target for glial cell line-derived neuro-
trophic factor expression induced by antidepressants. J Biol 
Chem 291:27364–27370.
Kragh J, Bolwig TG, Woldbye DP, Jørgensen OS (1993) Electrocon-
vulsive shock and lidocaine-induced seizures in the rat acti-
vate astrocytes as measured by glial fibrillary acidic protein. 
Biol Psychiatry 33:794–800.
Kunugi H, et al. (2006) Assessment of the dexamethasone/CRH 
test as a state-dependent marker for hypothalamic-pituitary-
adrenal (HPA) axis abnormalities in major depressive episode: 
a multicenter study. Neuropsychopharmacology 31:212–220.
Kurano M, Suzuki A, Inoue A, Tokuhara Y, Kano K, Matsumoto H, 
Igarashi  K, Ohkawa  R, Nakamura  K, Dohi  T, Miyauchi  K, 
Daida H, Tsukamoto K, Ikeda H, Aoki J, Yatomi Y (2015) Pos-
sible involvement of minor lysophospholipids in the increase 
in plasma lysophosphatidic acid in acute coronary syndrome. 
Arterioscler Thromb Vasc Biol 35:463–470.
Madsen TM, Yeh DD, Valentine GW, Duman RS (2005) Electrocon-
vulsive seizure treatment increases cell proliferation in rat 
frontal cortex. Neuropsychopharmacology 30:27–34.
Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, 
Higashi  K, Yokota  H, Okudaira  S, Kishimoto  T, Watanabe  T, 
Koike Y, Ikeda H, Kozai Y, Kurokawa M, Aoki J, Yatomi Y (2008) 
Serum autotaxin measurement in haematological malignan-
cies: a promising marker for follicular lymphoma. Br J Hae-
matol 143:60–70.
Matas-Rico  E, García-Diaz  B, Llebrez-Zayas  P, López-Barroso  D, 
Santín L, Pedraza C, Smith-Fernández A, Fernández-Llebrez P, 
Tellez  T, Redondo  M, Chun  J, De  Fonseca  FR, Estivill-Tor-
rús G (2008) Deletion of lysophosphatidic acid receptor LPA1 
reduces neurogenesis in the mouse dentate gyrus. Mol Cell 
Neurosci 39:342–355.
Moreno-Fernández  RD, Pérez-Martín  M, Castilla-Ortega  E, 
Rosell  Del  Valle  C, García-Fernández  MI, Chun  J, Estivill-
Torrús G, Rodríguez de Fonseca F, Santín LJ, Pedraza C (2017) 
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz005/5306018 by guest on 13 M
arch 2019
Copyedited by: oup
Itagaki et al. | 9
maLPA1-null mice as an endophenotype of anxious depres-
sion. Transl Psychiatry 7:e1077.
Nakamura K, Igarashi K, Ide K, Ohkawa R, Okubo S, Yokota H, 
Masuda  A, Oshima  N, Takeuchi  T, Nangaku  M, Okudaira  S, 
Arai H, Ikeda H, Aoki J, Yatomi Y (2008) Validation of an auto-
taxin enzyme immunoassay in human serum samples and 
its application to hypoalbuminemia differentiation. Clin 
Chim Acta 388:51–58.
Nakamura K, Ohkawa R, Okubo S, Yokota H, Ikeda H, Yatomi Y, 
Igarashi K, Ide K, Kishimoto T, Masuda A, Yamamoto T, Tsuji S, 
Saito N, Kurokawa M, Okudaira S, Aoki J (2009) Autotaxin en-
zyme immunoassay in human cerebrospinal fluid samples. 
Clin Chim Acta 405:160–162.
Olianas MC, Dedoni S, Onali P (2016) LPA1 mediates antidepres-
sant-induced ERK1/2 signaling and protection from oxidative 
stress in glial cells. J Pharmacol Exp Ther 359:340–353.
Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, Aoy-
ama H, Mimura M, Kamijima K (2005) Reliability and validity 
of Japanese version of the Mini-International Neuropsychi-
atric Interview. Psychiatry Clin Neurosci 59:517–526.
Petrides G, Fink M (1996) The “half-age” stimulation strategy for 
ECT dosing. Convuls Ther 12:138–146.
Rajkowska  G, Mahajan  G, Maciag  D, Sathyanesan  M, Iyo  AH, 
Moulana M, Kyle PB, Woolverton WL, Miguel-Hidalgo JJ, Stock-
meier CA, Newton SS (2015) Oligodendrocyte morphometry and 
expression of myelin-related mRNA in ventral prefrontal white 
matter in major depressive disorder. J Psychiatr Res 65:53–62.
Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major 
depressive disorder: insights from human postmortem brain 
tissue. Curr Drug Targets 14:1225–1236.
Sanacora G, Banasr M (2013) From pathophysiology to novel anti-
depressant drugs: glial contributions to the pathology and 
treatment of mood disorders. Biol Psychiatry 73:1172–1179.
Santin  LJ, Bilbao  A, Pedraza  C, Matas-Rico  E, López-Barroso  D, 
Castilla-Ortega  E, Sánchez-López  J, Riquelme  R, Varela-
Nieto I, de la Villa P, Suardíaz M, Chun J, De Fonseca FR, Estiv-
ill-Torrús G (2009) Behavioral phenotype of malpa1-null mice: 
increased anxiety-like behavior and spatial memory deficits. 
Genes Brain Behav 8:772–784.
Savaskan  NE, Rocha  L, Kotter  MR, Baer  A, Lubec  G, van  Mee-
teren LA, Kishi Y, Aoki J, Moolenaar WH, Nitsch R, Bräuer AU 
(2007) Autotaxin (NPP-2) in the brain: cell type-specific ex-
pression and regulation during development and after neu-
rotrauma. Cell Mol Life Sci 64:230–243.
Schilling T, Stock C, Schwab A, Eder C (2004) Functional import-
ance of Ca2+-activated K+ channels for lysophosphatidic acid-
induced microglial migration. Eur J Neurosci 19:1469–1474.
Seretti A, Cusin C, Lattuada E, Di Bella D, Catalano M, Smeraldi E 
(1999) Serotonin transporter gene (5-HTTLPR) is not associ-
ated with depressive symptomatology in mood disorders. 
Mol Psychiatry 4:280–283.
Sheehan  DV, Lecrubier  Y, Sheehan  KH, Amorim  P, Janavs  J, 
Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-
International Neuropsychiatric Interview (M.I.N.I.): the devel-
opment and validation of a structured diagnostic psychiatric 
interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 
20):22–33;quiz 34.
Shibasaki C, Takebayashi M, Itagaki K, Abe H, Kajitani N, Okada-
Tsuchioka M, Yamawaki S (2016) Altered serum levels of matrix 
metalloproteinase-2, -9 in response to electroconvulsive therapy 
for mood disorders. Int J Neuropsychopharmacol 19:1–8.
Shimizu M, Furuichi K, Toyama T, Yamahana  J, Ohkawa R, Iga-
rashi  K, Aoki  J, Kaneko  S, Yatomi  Y, Wada  T (2016) Serum 
autotaxin levels are associated with proteinuria and kidney 
lesions in japanese type 2 diabetic patients with biopsy-
proven diabetic nephropathy. Intern Med 55:215–221.
Sumida  H, Nakamura  K, Yanagida  K, Ohkawa  R, Asano  Y, 
Kadono  T, Tamaki  K, Igarashi  K, Aoki  J, Sato  S, Ishii  S, 
Shimizu  T, Yatomi  Y (2013) Decrease in circulating auto-
taxin by oral administration of prednisolone. Clin Chim Acta 
415:74–80.
Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi  I, 
Kozuru  T, Hikasa  S, Okamoto  Y, Shinno  H, Morinobu  S, 
Yamawaki S (2006) Decreased levels of whole blood glial cell 
line-derived neurotrophic factor (GDNF) in remitted patients 
with mood disorders. Int J Neuropsychopharmacol 9:607–612.
Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, 
Yatomi Y, Aoki J, Arai H (2006) Autotaxin stabilizes blood ves-
sels and is required for embryonic vasculature by producing 
lysophosphatidic acid. J Biol Chem 281:25822–25830.
Tham  MW, Woon  PS, Sum  MY, Lee  TS, Sim  K (2011) White 
matter abnormalities in major depression: evidence from 
post-mortem, neuroimaging and genetic studies. J Affect Dis-
ord 132:26–36.
Trimbuch  T, et  al. (2009) Synaptic PRG-1 modulates excitatory 
transmission via lipid phosphate-mediated signaling. Cell 
138:1222–1235.
Tsybko AS, Ilchibaeva TV, Popova NK (2017) Role of glial cell line-
derived neurotrophic factor in the pathogenesis and treat-
ment of mood disorders. Rev Neurosci 28:219–233.
Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, 
Suzuki  T, Miyata  N, Watanabe  Y (2011) Epigenetic status of 
gdnf in the ventral striatum determines susceptibility and 
adaptation to daily stressful events. Neuron 69:359–372.
Umemura K, Yamashita N, Yu X, Arima K, Asada T, Makifuchi T, 
Murayama S, Saito Y, Kanamaru K, Goto Y, Kohsaka S, Kanaz-
awa I, Kimura H (2006) Autotaxin expression is enhanced in 
frontal cortex of alzheimer-type dementia patients. Neurosci 
Lett 400:97–100.
Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, 
Yamori T, Mills GB, Inoue K, Aoki J, Arai H (2002) Autotaxin has 
lysophospholipase D activity leading to tumor cell growth 
and motility by lysophosphatidic acid production. J Cell Biol 
158:227–233.
van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooi-
jen MA, Pradère JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, 
Mummery  CL, Moolenaar  WH, Jonkers  J (2006) Autotaxin, a 
secreted lysophospholipase D, is essential for blood vessel 
formation during development. Mol Cell Biol 26:5015–5022.
Wang Q, Jie W, Liu JH, Yang JM, Gao TM (2017) An astroglial basis 
of major depressive disorder? An overview. Glia 65:1227–1250.
Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, 
Hama K, Okudaira S, Tanaka M, Tomiya T, Yanase M, Tejima K, 
Nishikawa T, Arai M, Arai H, Omata M, Fujiwara K, Yatomi Y 
(2007) Both plasma lysophosphatidic acid and serum auto-
taxin levels are increased in chronic hepatitis C. J Clin Gas-
troenterol 41:616–623.
Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, Kings-
bury MA, Chun J (2011) Lysophosphatidic acid signaling may 
initiate fetal hydrocephalus. Sci Transl Med 3:99ra87.
Yung YC, Stoddard NC, Mirendil H, Chun J (2015) Lysophospha-
tidic acid signaling in the nervous system. Neuron 85:669–682.
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, 
Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Lid-
delow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ 
(2014) An RNA-sequencing transcriptome and splicing data-
base of glia, neurons, and vascular cells of the cerebral cortex. 
J Neurosci 34:11929–11947.
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/advance-article-abstract/doi/10.1093/ijnp/pyz005/5306018 by guest on 13 M
arch 2019
